Regeneron Pharmaceuticals Inc (REGN)
906.54
-0.78
(-0.09%)
USD |
NASDAQ |
Apr 24, 16:00
906.80
+0.26
(+0.03%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Financing (Quarterly): -446.10M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -446.10M |
| September 30, 2023 | -407.30M |
| June 30, 2023 | -614.20M |
| March 31, 2023 | -322.50M |
| December 31, 2022 | -247.60M |
| September 30, 2022 | -725.00M |
| June 30, 2022 | -101.10M |
| March 31, 2022 | 64.70M |
| December 31, 2021 | -906.60M |
| September 30, 2021 | 385.40M |
| June 30, 2021 | -118.20M |
| March 31, 2021 | -366.40M |
| December 31, 2020 | -305.30M |
| September 30, 2020 | 612.00M |
| June 30, 2020 | -2.613B |
| March 31, 2020 | 335.60M |
| December 31, 2019 | -345.70M |
| September 30, 2019 | -11.00M |
| June 30, 2019 | -15.30M |
| March 31, 2019 | 119.90M |
| December 31, 2018 | -83.00M |
| September 30, 2018 | 3.70M |
| June 30, 2018 | -11.20M |
| March 31, 2018 | 13.40M |
| December 31, 2017 | -210.54M |
| Date | Value |
|---|---|
| September 30, 2017 | -8.196M |
| June 30, 2017 | 133.52M |
| March 31, 2017 | 60.81M |
| December 31, 2016 | -491.79M |
| September 30, 2016 | 28.68M |
| June 30, 2016 | -31.20M |
| March 31, 2016 | -206.19M |
| December 31, 2015 | -4.008M |
| September 30, 2015 | -345.65M |
| June 30, 2015 | -3.535M |
| March 31, 2015 | 90.40M |
| December 31, 2014 | -252.66M |
| September 30, 2014 | 5.166M |
| June 30, 2014 | -80.01M |
| March 31, 2014 | 108.95M |
| December 31, 2013 | 100.62M |
| September 30, 2013 | 3.533M |
| June 30, 2013 | -43.48M |
| March 31, 2013 | 11.52M |
| December 31, 2012 | -73.01M |
| September 30, 2012 | -1.809M |
| June 30, 2012 | -5.077M |
| March 31, 2012 | -17.75M |
| December 31, 2011 | 361.44M |
| September 30, 2011 | -0.279M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.613B
Minimum
Jun 2020
612.00M
Maximum
Sep 2020
-323.55M
Average
-305.30M
Median
Dec 2020
Cash from Financing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -119.80M |
| Eli Lilly and Co | 3.545B |
| AbbVie Inc | -4.449B |
| Amgen Inc | 2.754B |
| Pfizer Inc | 5.442B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.090B |
| Cash from Investing (Quarterly) | -66.20M |
| Free Cash Flow | 3.668B |
| Free Cash Flow Per Share (Quarterly) | 6.827 |
| Free Cash Flow to Equity (Quarterly) | 775.90M |
| Free Cash Flow to Firm (Quarterly) | 776.20M |
| Free Cash Flow Yield | 3.56% |